Evidence map›Paper›PMID 25381819›Full record

ArticleOncogene2015

Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.

G Sriram, W Jankowski, C Kasikara, C Reichman, T Saleh, K-Q Nguyen, J Li, P Hornbeck, K Machida, T Liu and 3 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

G SriramDepartment of Biochemistry and Molecular Biology, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
W JankowskiDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
C KasikaraDepartment of Biochemistry and Molecular Biology, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
C ReichmanDepartment of Biochemistry and Molecular Biology, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
T SalehDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
K-Q NguyenDepartment of Biochemistry and Molecular Biology, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
J LiCell Signaling Technology, Danvers, MA, USA.
P HornbeckCell Signaling Technology, Danvers, MA, USA.
K MachidaRaymond and Beverly Sackler Laboratory of Genetics and Molecular Medicine, Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT, USA.
T LiuCenter for Advanced Proteomic Research, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
H LiCenter for Advanced Proteomic Research, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
C G KalodimosDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
R B BirgeDepartment of Biochemistry and Molecular Biology, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Rutgers, The State University of New Jersey · USCell Signaling Technology (United States) · USRutgers Health

Funding

Rutgers Mass Spectrometry Core for Integrative Neuroscience ResearchP30NS046593 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI LI, HONG, LOBEL, PETER · 2004 to 2018
$9.9M
Regulatory mechanisms of the Crk Adapter proteinR01GM080308 · NIGMS · UNIVERSITY OF MINNESOTA · PI KALODIMOS, CHARALAMPOS · 2007 to 2015
$2.7M
Non-canonical Signal Pathway for Crk in Breast CancerR01CA165077 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BIRGE, RAYMOND B. · 2012 to 2016
$1.7M
NCI NIH HHS CA165077NCI NIH HHS R01 CA165077NIGMS NIH HHS GM080308NIGMS NIH HHS R01 GM080308NINDS NIH HHS NS046593NINDS NIH HHS P30 NS046593
6 · The paper itself

Abstract

Crk, the prototypical member of a class of Src homology-2 (SH2) and Src homology-3 (SH3) domain containing proteins that controls the coordinated assembly of signaling complexes, is regulated by phosphorylation of Y221 in the linker region, which forms an intramolecular SH2-pY221 auto-clamp to interrupt SH2-N-terminal SH3 domain (SH3N) signaling. Here, we show using LC-MS/MS and by generating phospho-specific antibodies that, iteratively with Y221, the Crk C-terminal SH3 domain (SH3C) is routinely phosphorylated on Y239 and/or Y251 by several extracellular stimuli known to engage Crk. Although phosphorylation at Y221 auto-inhibits the Crk SH2, phosphorylation of the SH3C generates an unconventional phosphoSH3C-SH3N unit in which the SH3N is fully functional to bind polyproline type II ligands and the phosphoSH3C binds de novo to other SH2 domains. Using high-throughput SH2 domain profiling, artificial neural network and position-specific scoring matrix-based bioinformatics approaches, and unbiased mass spectometry, we found that the phosphoSH3C binds several SH2 domain containing proteins, including specific non-receptor tyrosine kinases-Abl via pY251 and C-terminal Src kinase via pY239. Functionally, we show that the phosphoSH3C modulates the Abl-mediated phenotypes of cell spreading and motility. Together, these studies describe a versatile mechanism wherein phosphorylation of Crk at Y221 is not an off switch but redirects signaling from the SH2-SH3N axis to a phosphoSH3C-SH3N axis, with the SH3N as a common denominator.

Indexed as

Signal Transductionsrc Homology DomainsAmino Acid SequenceAnimalsBlotting, WesternCell Line, TumorChromatography, LiquidHEK293 CellsHumansMiceMolecular Sequence DataNIH 3T3 CellsOncogene Proteins v-ablPhosphorylationProtein BindingProto-Oncogene Proteins c-crkCRK protein, humanOncogene Proteins v-ablProto-Oncogene Proteins c-crkTyrosine

Identifiers

PMID25381819
PMCPMC4706174
OpenAlexW1968102934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.